Equillium, Inc. (0FY.F)
| Previous Close | 0.5040 |
| Open | 0.4625 |
| Bid | 0.4915 x 0 |
| Ask | 0.5100 x 0 |
| Day's Range | 0.4625 - 0.4625 |
| 52 Week Range | 0.4035 - 1.5600 |
| Volume | |
| Avg. Volume | 232 |
| Market Cap | 16.243M |
| Beta (5Y Monthly) | 1.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2000 |
| Earnings Date | Nov 08, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.00 |
PR NewswireEQ Bank Card launches in Québec as Carte Banque EQ
EQ Bank (Banque EQ in Québec) is offering Québec customers a new way to earn, save and spend their money, with the introduction of its popular EQ Bank Card1 (Carte Banque EQ). Customers can use the card to withdraw cash for free at any ATM in the country, earn cash back on their spending, earn high interest on their card balance, and travel without paying foreign currency conversion fees.
Business WireEquillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology
LA JOLLA, Calif., November 13, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that data from the Type B portion of the EQUALISE study evaluating itolizumab in lupus nephritis patients was presented at ACR Convergence, the annual meeting of the American College of Rheumatology (ACR). The data presented by Dr. Kenneth Kalunian, Professor, Medicine, UCSD School
Business WireEquillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
LA JOLLA, Calif., November 08, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2023 and provided corporate and clinical development updates.
